| Literature DB >> 32867740 |
Zheng Peng1, Jin'an Zhou2, Lei Tian3.
Abstract
BACKGROUND: Lower respiratory tract infection (LRIs) is very common both in terms of community-acquired infection and hospital-acquired infection. Sputum and bronchoalveolar lavage fluid (BALF) are the most important specimens obtained from patients with LRI. The choice of antibiotic with which to treat LRI usually depends on the antimicrobial sensitivity of bacteria isolated from sputum and BALF. However, differences in the antimicrobial sensitivity of pathogens isolated from sputum and BALF have not been evaluated.Entities:
Keywords: Bronchoalveolar lavage fluid; Lower respiratory tract infection; Sputum
Mesh:
Substances:
Year: 2020 PMID: 32867740 PMCID: PMC7460743 DOI: 10.1186/s12890-020-01275-8
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Fig. 1Distribution of pathogens isolated from sputum and BALF (top 10). a Distribution of pathogens from sputum specimens in 2013–2015. b Distribution of pathogens from BALF specimens in 2013–2015. c Distribution of pathogens from sputum specimens in 2016–2018. d Distribution of pathogens from BALF specimens in 2016–2018
Sensitivity rate of Pseudomonas aeruginosa isolated from sputum and BALF to commonly used antibiotics
| Antibiotics | 2013–2015 | 2016–2018 | ||||
|---|---|---|---|---|---|---|
| BALF | Sputum | BALF | sputum | |||
| Piperacillin | 75 | 57.3 | < 0.01 | 68.2 | 55.8 | |
| Cefoperazone/sulbactam | 72.7 | 58.1 | < 0.01 | 71.8 | 54.6 | |
| Ticarcillin/clavulanic acid | 40.3 | 12.4 | < 0.01 | 40.3 | 10.8 | |
| Piperacillin/tazobactam | 79.3 | 62.8 | < 0.01 | 74.6 | 61.7 | |
| Cefoperazone | 64.2 | 49.6 | < 0.01 | 65.1 | 48.2 | |
| Ceftazidime | 80.5 | 64.5 | < 0.01 | 73.4 | 62.3 | |
| Cefepime | 81.1 | 64.5 | < 0.01 | 78.1 | 68.5 | |
| Aztreonam | 71.3 | 53.8 | < 0.01 | 63.5 | 46.8 | |
| Imipenem | 72 | 63.2 | 0.01 < | 68.6 | 57.4 | |
| Meropenem | 81 | 64.1 | < 0.01 | 74.4 | 61.7 | |
| Amikacin | 88.4 | 72.7 | < 0.01 | 87.6 | 86.4 | |
| Gentamicin | 82.1 | 61.8 | < 0.01 | 80.5 | 79.4 | |
| Tobramycin | 88.4 | 70.4 | < 0.01 | 87.8 | 84 | |
| Ciprofloxacin | 71.3 | 65 | 75.6 | 67.1 | ||
| Levofloxacin | 64.2 | 58.1 | 68.9 | 61.2 | ||
| Trimethoprim sulfamethoxazole | 21.6 | 7.8 | < 0.01 | 14.3 | 5.5 | |
| Minocycline | 35 | 13.2 | < 0.01 | 31.6 | 14 | |
Sensitivity rate of Acinetobacter baumannii isolated from sputum and BALF to commonly used antibiotics
| Antibiotics | 2013–2015 | 2016–2018 | ||||
|---|---|---|---|---|---|---|
| BALF | sputum | BALF | sputum | |||
| Piperacillin | 25.8 | 7.9 | 2.2 | 2.3 | ||
| Cefoperazone/sulbactam | 14.1 | 17.8 | 9.3 | 6.1 | 0.01 < | |
| Ampicillin/sulbactam | 14.2 | 16.7 | 9.3 | 5.7 | 0.01 < | |
| Piperacillin/tazobactam | 32.1 | 14.8 | 7.1 | 4 | 0.01 < | |
| Ceftazidime | 27.1 | 8.4 | 4.8 | 3.1 | ||
| Cefepime | 32.1 | 16.6 | 9 | 5.2 | ||
| Aztreonam | 0.6 | 1.5 | 0.6 | 0.2 | ||
| Imipenem | 11 | 16.9 | 9.6 | 5.5 | ||
| Meropenem | 10.9 | 15.8 | 9.3 | 5 | ||
| Amikacin | 12.8 | 21.4 | 0.01 < | 14.7 | 10 | 0.01 < |
| Gentamicin | 9.6 | 14.8 | 9.6 | 5.5 | ||
| Tobramycin | 10.9 | 18.1 | 0.01 < | 12.8 | 7.5 | |
| Ciprofloxacin | 15.4 | 17.4 | 8.3 | 4.7 | ||
| Levofloxacin | 31.4 | 18.2 | 9 | 5 | ||
| Trimethoprim sulfamethoxazole | 33.3 | 16.7 | 10.3 | 6.7 | 0.01 < | |
| Minocycline | 38.7 | 33.8 | 33.4 | 35.3 | ||
| Tegacycline | 34.8 | 46.3 | 43.4 | 46.4 | ||
Sensitivity rate of Klebsiella pneumoniae isolated from sputum and BALF to commonly used antibiotics
| Antibiotics | 2013–2015 | 2016–2018 | ||||
|---|---|---|---|---|---|---|
| BALF | Sputum | BALF | Sputum | |||
| Piperacillin | 31 | 23.7 | 22.6 | 7 | ||
| Amoxicillin/clavulanic acid | 59.6 | 43 | 53.8 | 21.3 | ||
| Cefoperazone/sulbactam | 70.4 | 53.9 | 56.1 | 24.1 | ||
| Ampicillin/sulbactam | 53.4 | 33.8 | 49.7 | 15.7 | ||
| Piperacillin/tazobactam | 75 | 61.1 | 58.5 | 28.6 | ||
| Cefazolin | 36.2 | 25.1 | 42 | 12.8 | ||
| Cefuroxime | 56 | 34 | 49.9 | 16.6 | ||
| Ceftazidime | 69.8 | 50.4 | 54.8 | 23.8 | ||
| Cefotaxime | 57.4 | 36.2 | 51.9 | 17.9 | ||
| Cefepime | 61.4 | 38.2 | 53.8 | 19.2 | ||
| Cefoxitin | 77.6 | 65.6 | 59.2 | 32.6 | ||
| Aztreonam | 69 | 48.9 | 54.8 | 21.4 | ||
| Imipenem | 90.5 | 81.3 | 0.01 < | 67.3 | 40.3 | |
| Meropenem | 90.5 | 81 | 0.01 < | 67.7 | 40.6 | |
| Amikacin | 87.8 | 83.3 | 70.6 | 52.2 | ||
| Gentamicin | 66.4 | 58.4 | 61.4 | 38.5 | ||
| Tobramycin | 61.2 | 55.5 | 57.8 | 36.6 | ||
| Ciprofloxacin | 69.6 | 60.4 | 55.3 | 22.6 | ||
| Levofloxacin | 75.9 | 71.2 | 59.9 | 28.3 | ||
| Trimethoprim sulfamethoxazole | 67.2 | 56.9 | 0.01 < | 64.5 | 55.7 | |
| Tegacycline | 87.2 | 87.1 | 92.3 | 89.2 | ||
Sensitivity rate of Staphylococcus aureus isolated from sputum and BALF to commonly used antibiotics
| Antibiotics | 2013–2015 | 2016–2018 | ||||
|---|---|---|---|---|---|---|
| BALF | sputum | BALF | sputum | |||
| Penicillin G | 1.9 | 1.5 | 3.2 | 0.9 | ||
| Oxacillin | 30.2 | 19.9 | 32.5 | 15.6 | ||
| Ampicillin/sulbactam | 30.8 | 19.4 | 31.6 | 15.6 | ||
| Cefazolin | 30.8 | 19.3 | 30.9 | 15.5 | ||
| Cefuroxime | 30.8 | 19.9 | 32.5 | 15.6 | ||
| Cefoxitin | 30.8 | 20 | 32.5 | 15.5 | ||
| Gentamicin | 32.7 | 24.6 | 41.6 | 24 | ||
| Tobramycin | 32.7 | 23.1 | 0.01 < | 39.7 | 22.6 | |
| Rifampicin | 47.7 | 30.3 | 88.7 | 83.3 | 0.01 < | |
| Levofloxacin | 28.3 | 23.8 | 39.8 | 19.1 | ||
| Trimethoprim sulfamethoxazole | 92.5 | 96.9 | 0.01 < | 97.2 | 96.9 | |
| Fosfomycin | 83.5 | 80.6 | 51.9 | 37.7 | ||
| Clindamycin | 68.9 | 69.6 | 35.7 | 24.1 | ||
| Erythromycin | 46.7 | 52.6 | 26.5 | 15.6 | ||
| Linezolid | 100 | 100 | 100 | 100 | ||
| Vancomycin | 100 | 100 | 100 | 100 | ||
| Teicoplanin | 100 | 100 | 100 | 100 | ||
| Tegacycline | 92.9 | 90.2 | 94.6 | 93.6 | ||